Meeting
2020 ASCO Virtual Scientific Program
Validity of patient-reported outcomes to describe the symptom experience of patients enrolled on phase I clinical trials.
Presenter
Ramy Sedhom, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT01828775
Citation
J Clin Oncol 38: 2020 (suppl; abstr 12107)
DOI
10.1200/JCO.2020.38.15_suppl.12107
Abstract #
12107
Poster Bd #
395
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Breakthrough
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
Speaker: Eiji Kikuchi, PhD
Videos & Slides
2024 ASCO Breakthrough
CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor.
Speaker: Hidekazu Hirano, MD, PhD
Speaker: Ryan David Nipp, MD
Videos & Slides
2024 ASCO Annual Meeting
Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).
Speaker: Vania Hungria, MD, PhD